Fig. 2: Improvements in metabolic factors are correlated with MASH resolution without worsening of fibrosis.
a, On-treatment observations using an MMRM. Data are partially presented in the primary publication. Differences between semaglutide and placebo were assessed using a two-sided t-test. HbA1c and FPG are reported in patients with T2D only, and HOMA-IR and Adipo-IR (fasting plasma insulin × FFA) are reported in patients not treated with insulin at baseline. b–j, Data for change from baseline are mean ± s.e.m. and, for ratio to baseline, geometric mean ± s.e.m. calculated on a log scale and then back-transformed. Data are from the on-treatment observation period for individuals with available data (complete-case). b, Waist circumference (n = 40, n = 20, n = 14 and n = 49, respectively). c, HbA1c in individuals with and without T2D (n = 39, n = 20, n = 14 and n = 48, respectively). d, FPG in individuals both with and without T2D (n = 40, n = 20, n = 14 and n = 48, respectively). e, HDL-C (n = 40, n = 20, n = 14 and n = 48, respectively). f, Non-HDL-C (n = 40, n = 20, n = 14 and n = 48, respectively). g, Triglycerides (n = 40, n = 20, n = 14 and n = 48, respectively). h, hs-CRP (n = 40, n = 20, n = 14 and n = 48, respectively). i, HOMA-IR in individuals not treated with insulin at baseline (n = 39, n = 19, n = 11 and n = 40, respectively). j, Adipo-IR in individuals not treated with insulin at baseline (n = 39, n = 19, n = 11 and n = 39, respectively). Adipo-IR, adipose tissue insulin resistance (fasting plasma insulin × FFA); ETD, estimated treatment difference; ETR, estimated treatment ratio; FFA, free fatty acids; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; s.e.m., standard error of the mean.
